Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial
Inserm · Université Paris Cité · +16 more institutions
Indexed incrossrefpubmed
Abstract
Background
Aldosterone dysregulation is an important contributor in the pathogenesis of hard-to-control hypertension. We aimed to assess the effect of baxdrostat, a selective aldosterone synthase inhibitor, on ambulatory blood pressure in patients with resistant hypertension.
Methods
The Bax24 international, phase 3, randomised, double-blind, placebo-controlled trial recruited adults (aged ≥18 years) with seated systolic blood pressure (SBP) ≥140 mm Hg and
Citation impact
5
total citations
- FWCI
- 72.04
- Percentile
- 100%
- References
- 29
Too recent for citation history.
Authors
131Topics & keywords
Topics
Keywords
- Resistant hypertension
- Ambulatory blood pressure
- Blood pressure
- Ambulatory
- Phase (matter)
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.